Your browser doesn't support javascript.
loading
Predicting subgroup treatment effects for a new study: Motivations, results and learnings from running a data challenge in a pharmaceutical corporation.
Bornkamp, Björn; Zaoli, Silvia; Azzarito, Michela; Martin, Ruvie; Müller, Carsten Philipp; Moloney, Conor; Capestro, Giulia; Ohlssen, David; Baillie, Mark.
Affiliation
  • Bornkamp B; Global Drug Development, Novartis Pharma AG, Basel, Switzerland.
  • Zaoli S; Global Drug Development, Novartis Pharma AG, Basel, Switzerland.
  • Azzarito M; Global Drug Development, Novartis Pharma AG, Basel, Switzerland.
  • Martin R; Global Drug Development, Novartis Pharmaceuticals Corporation, East Hanover, New Jersey, USA.
  • Müller CP; Data Digital, Beyond Conception GmbH, Altendorf, Switzerland.
  • Moloney C; Global Drug Development, Novartis Pharma AG, Dublin, Ireland.
  • Capestro G; Global Drug Development, Novartis Pharma AG, Basel, Switzerland.
  • Ohlssen D; Global Drug Development, Novartis Pharmaceuticals Corporation, East Hanover, New Jersey, USA.
  • Baillie M; Global Drug Development, Novartis Pharma AG, Basel, Switzerland.
Pharm Stat ; 23(4): 495-510, 2024.
Article in En | MEDLINE | ID: mdl-38326967
Subject(s)
Key words
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Clinical Trials, Phase III as Topic / Motivation Type of study: Prognostic_studies / Risk_factors_studies Limits: Humans Language: En Journal: Pharm Stat Journal subject: FARMACOLOGIA Year: 2024 Type: Article Affiliation country: Switzerland
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Clinical Trials, Phase III as Topic / Motivation Type of study: Prognostic_studies / Risk_factors_studies Limits: Humans Language: En Journal: Pharm Stat Journal subject: FARMACOLOGIA Year: 2024 Type: Article Affiliation country: Switzerland